The UK and US have hammered out a significant commercial pact that will ensure zero levies on UK pharmaceutical exports going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on drugs through the public health system. This commitment guarantees that import taxes on these crucial exports will be held at zero for a period of the next three years.
This agreement is in response to recent statements to significantly raise import taxes on branded drug products, with potential rates mentioned as high as 100%.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and introduces much-needed equity to American-British pharmaceutical trade," an announcement noted.
Economic Significance
Medicines constitute one of the the United Kingdom's most significant export categories to the US, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period prior to the third quarter, the UK shipped drugs totaling over eleven billion pounds to the US. This value represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects work, stimulates investment and sets the stage for the UK to become a worldwide center for life sciences," a government official commented.
Key UK Commitments
The agreement includes several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to double total public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, refunds topped 20%.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were heightened by assertions that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while substantial expansions have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had declined as a share of its resources over the previous ten-year period.
